drugset
drugset / Trial / NCT05149274

Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects

NCT05149274 ↗

Phase 1 Completed 32 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupOpen-labelTreatment

Summary

The pharmacokinetics (PK) and safety of oral DWP14012 tablet A will be evaluated and compared with those of DWP14012 tablet B in healthy subjects.

Timeline

Start
2021-10-01
Primary completion
2021-10-26
Completion
2021-10-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABEPRAZAN Small molecule 10 mg Oral
Comparator ABEPRAZAN Small molecule 40 mg Oral

Indications

No indication recorded.